Pneumonia Clinical Trial
— VANGARDOfficial title:
A Randomized, Double-Blind, Parallel Group Study to Assess the Efficacy and Safety of Once Weekly Subcutaneous Injections of Pemziviptadil (PB1046), a Sustained-Release VIP (Vasoactive Intestinal Peptide) ANalogue, in Hospitalized COVID-19 Patients at HiGh Risk for Rapid Clinical Deterioration and ARDS (PB1046 VANGARD Study)
Verified date | December 2020 |
Source | PhaseBio Pharmaceuticals Inc. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is a multicenter, randomized, double-blind, parallel group study to investigate the efficacy of pemziviptadil (PB1046) by improving the clinical outcomes in hospitalized COVID-19 patients at high risk for rapid clinical deterioration, acute respiratory distress syndrome (ARDS) and death. The study will enroll approximately 210 hospitalized COVID-19 patients who require urgent decision-making and treatment at approximately 20 centers in the United States.
Status | Terminated |
Enrollment | 54 |
Est. completion date | December 2, 2020 |
Est. primary completion date | December 2, 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 85 Years |
Eligibility | Inclusion Criteria: 1. Written or witnessed verbal informed consent from patient or remote legal authorized representative (LAR) or remote family member as permitted by governing local or central Institutional Review Board (IRB)/independent Ethic Committee (IEC). 2. Male or female 18-85 years old hospitalized COVID-19 patients (positive local SARS-CoV2 test) 3. Receiving oxygen (O2) by face mask or nasal cannula/prongs and/or with elevated markers of cardiac injury or dysfunction (hsTnI or NT-proBNP) as assessed by local testing Exclusion Criteria: Subjects will be excluded from the study if they meet any of the following criteria: 1. Patients considered unsalvageable or expected to expire within 24 hours 2. On mechanical ventilation or imminent need for mechanical ventilation expected in the next 24 hours 3. Evidence of acute end-organ injury in 2 or more organ systems (not including cardiac or pulmonary), such as, renal, hepatic, or CNS injury 4. Receiving another investigational therapy for treatment or prevention of COVID-19-related hypoxemic respiratory failure or ARDS other than antiviral therapy 5. Systolic blood pressure (SBP) < 95 mmHg and/or diastolic blood pressure (DBP) < 50 mmHg or overt symptomatic hypotension during screening 6. Resting heart rate > 110 BPM (beats per minute) during screening 7. Severe chronic renal failure as measured by the estimated glomerular filtration rate (eGFR) of < 30 mL/min/1.73m2 using the local laboratory calculation of eGFR. 8. Significant liver dysfunction as measured by any one of the following at screening: - ALT (Alanine transaminase) > 3.0 times ULN (upper limit of normal) - AST (Aspartate transaminase) > 3.0 times ULN - Serum bilirubin = 1.6 mg/dL 9. Any in-patient surgical procedure or hospitalization (defined as > 23 hours) within 30 days of subject screening except for prior hospitalization for COVID-19 10. Known hypersensitivity to study drug or any of the excipients of the drug formulation 11. Pregnant or lactating female subjects 12. Any other condition which, in the opinion of the Investigator, would place the subject at increased risk or would preclude obtaining informed consent or confound the objectives of study |
Country | Name | City | State |
---|---|---|---|
United States | Baptist Health Research Institute | Jacksonville | Florida |
United States | The University of Kansas Medical Center | Kansas City | Kansas |
United States | Sarasota Memorial Hospital | Sarasota | Florida |
United States | Adventist Healthcare White Oak Medical Center | Silver Spring | Maryland |
Lead Sponsor | Collaborator |
---|---|
PhaseBio Pharmaceuticals Inc. |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Impact on invasive hemodynamic parameters as measured by pulmonary artery pressure if patients require right-heart catherization | Any time point between injection initiation and Day 35+7 | ||
Other | Impact on invasive hemodynamic parameters as measured by cardiac output if patients require right-heart catherization | Any time point between injection initiation and Day 35+7 | ||
Other | Incidence of multi-system organ failure (MSOF) | Any time point between injection initiation and Day 35+7 | ||
Other | Number of multi-system organ failure (MSOF) free days | Any time point between injection initiation and Day 35+7 | ||
Other | Number of subjects requiring extracorporeal membrane oxygenation (ECMO) | Any time point between injection initiation and Day 35+7 | ||
Other | Change in circulating ferritin | Any time point between injection initiation and Day 35+7 | ||
Other | Change in circulating D-dimer | Any time point between injection initiation and Day 35+7 | ||
Other | Change in liver function | Any time point between injection initiation and Day 35+7 | ||
Other | Change in other blood chemistry | Any time point between injection initiation and Day 35+7 | ||
Other | Change in hematology | Any time point between injection initiation and Day 35+7 | ||
Other | Change in inflammatory markers | Any time point between injection initiation and Day 35+7 | ||
Other | Change in coagulation markers | Any time point between injection initiation and Day 35+7 | ||
Other | Percent of clinical failure | Any time point between injection initiation and Day 35+7 | ||
Primary | Time to clinical recovery from initiation of pemziviptadil (PB1046) | 28 days | ||
Secondary | Time to clinical recovery (being well enough for hospital discharge or returning to normal baseline activity level prior to discharge) | 28 days | ||
Secondary | Time to hospital discharge | Any time point between injection initiation and Day 28 | ||
Secondary | All-cause mortality | 28 days | ||
Secondary | Reduction in hospital resource utilization defined as a composite of: total days: in hospital, in ICU, on ventilator, on ECMO, with invasive hemodynamic monitoring, with mechanical circulatory support, and with inotropic or vasopressor therapy | Composite of: Total hospital days, Total ICU days, Total days of ventilator use, Total days of ECMO, Total days of invasive hemodynamic monitoring, Total days of mechanical circulatory support, Total days of inotropic or vasopressor therapy | 28 days | |
Secondary | Time to clinical improvement as defined by reduction of at least 2 points on an 8-category ordinal scale of clinical improvement or discharge from hospital, whichever comes first. | Any time point between injection initiation and Day 28 | ||
Secondary | Change from baseline in cardiac marker troponin I (TrI) | Any time point between injection initiation and Day 35+7 | ||
Secondary | Change from baseline in cardiac marker NT-proBNP/BNP | Any time point between injection initiation and Day 35+7 | ||
Secondary | Change from baseline in TNF alpha | Any time point between injection initiation and Day 35+7 | ||
Secondary | Change from baseline in IL-1 | Any time point between injection initiation and Day 35+7 | ||
Secondary | Change from baseline in IL-6 | Any time point between injection initiation and Day 35+7 | ||
Secondary | Incidence and severity of any treatment emergent adverse events (TEAEs) or serious adverse events (SAEs) as determined by clinical adverse events (AEs) and their relationship to pemziviptadil (PB1046). | Any time point between injection initiation and Day 35+7 | ||
Secondary | Incidence and severity of any treatment emergent adverse events (TEAEs) or serious adverse events (SAEs) as determined by vital signs and their relationship to pemziviptadil (PB1046) | Any time point between injection initiation and Day 35+7 | ||
Secondary | Incidence and severity of any treatment emergent adverse events (TEAEs) or serious adverse events (SAEs) as determined by laboratory results and their relationship to pemziviptadil (PB1046) | Any time point between injection initiation and Day 35+7 | ||
Secondary | Incidence and severity of any treatment emergent adverse events (TEAEs) or serious adverse events (SAEs) as determined by electrocardiogram (ECG) abnormalities and their relationship to pemziviptadil (PB1046) | Any time point between injection initiation and Day 35+7 | ||
Secondary | Incidence and severity of any treatment emergent adverse events (TEAEs) or serious adverse events (SAEs) as determined by incidence of anti-drug antibodies and their relationship to pemziviptadil (PB1046) | Any time point between injection initiation and Day 35+7 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT04244474 -
Effect of Vitamin D Supplementation on Improvement of Pneumonic Children
|
Phase 1/Phase 2 | |
Completed |
NCT05815264 -
Clinical Trial of 23-valent Pneumococcal Polysaccharide Vaccine in Healthy Chinese Population Aged 2 Years and Above
|
Phase 1 | |
Recruiting |
NCT04589936 -
Prone Position to Improve Oxygenation in COVID-19 Patients Outside Critical Care
|
N/A | |
Completed |
NCT02905383 -
The Effect of Exercise on Physical Function and Health in Older People After Discharge From Hospital
|
N/A | |
Terminated |
NCT03944551 -
Bubble Continuous Positive Airway Pressure for Children With Severe Pneumonia in Mali, Africa
|
N/A | |
Completed |
NCT06210737 -
A Study to Evaluate Persistence of Immunity of PCV13 in Healthy Population Aged 2 Months,7 Months-5 Years
|
Phase 4 | |
Terminated |
NCT04660084 -
Impact of Molecular Testing on Improved Diagnosis, Treatment and Management of CAP
|
N/A | |
Not yet recruiting |
NCT05649891 -
Checklists Resuscitation Emergency Department
|
N/A | |
Withdrawn |
NCT05702788 -
Efficacy and Safety of Jaktinib in Participants With Severe Novel Coronavirus Pneumonia(COVID-19)
|
Phase 2 | |
Not yet recruiting |
NCT04171674 -
Pharmacokinetics of High-dose Ceftobiprole in Community-acquired Pneumonia Under Mechanical Ventilation.
|
N/A | |
Active, not recruiting |
NCT03140163 -
Screening for Pneumonia: A Comparison of Ultra Low Dose Chest CT [ULD-CT] and Conventional Chest Radiography [CXR]
|
N/A | |
Completed |
NCT02638649 -
Prehospital Use of Ultrasound in Undifferentiated Shortness of Breath
|
||
Completed |
NCT02864420 -
Hospitalization at Home: The Acute Care Home Hospital Program for Adults
|
N/A | |
Recruiting |
NCT02515565 -
Physiotherapy in Patients Hospitalized Due to Pneumonia.
|
N/A | |
Completed |
NCT02105298 -
Effect of Volume and Type of Fluid on Postoperative Incidence of Respiratory Complications and Outcome (CRC-Study)
|
N/A | |
Completed |
NCT01446926 -
Study of Investigational Pneumococcal Vaccine in Healthy Adults, Toddlers and Infants
|
Phase 1 | |
Completed |
NCT01416519 -
Physiotherapy Technique Decreases Respiratory Complications After Cardiac Operation
|
N/A | |
Completed |
NCT01399723 -
Amoxicillin Versus Benzyl Penicillin for Treatment of Children Hospitalised With Severe Pneumonia
|
Phase 3 | |
Completed |
NCT01416506 -
Community-Acquired Pneumonia (CAP) Surveillance
|
N/A | |
Terminated |
NCT02358642 -
Drug to Prevent Pneumonia in the Tube Fed
|
Phase 4 |